Jamie Perse, an analyst from Goldman Sachs, maintained the Hold rating on HCA Healthcare. The associated price target is $332.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jamie Perse’s rating is based on HCA Healthcare’s recent financial performance, which showed a mixed picture. The company reported a stronger than expected EBITDA, surpassing consensus estimates by approximately 4%, driven by favorable pricing and mix, as well as effective expense management in labor and other operational costs. However, despite these positive aspects, the volume growth was below expectations, with same-facility admissions and equivalent admissions growth falling short of the company’s annual guidance.
While HCA has increased its guidance for the year, the current volume trends raise concerns about the sustainability of growth moving forward. The report also highlights the need for more information on the volume environment and guidance assumptions, particularly in relation to Medicaid DPP contributions and ACA exchange volume trends. These factors contribute to Jamie Perse’s decision to maintain a Hold rating, reflecting a cautious stance given the uncertainties in volume growth despite the company’s strong financial discipline.
In another report released on July 23, TR | OpenAI – 4o also downgraded the stock to a Hold with a $381.00 price target.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HCA in relation to earlier this year.